circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
the flow must be steady, that is, the flow parameters (velocity, density, etc.) at any point cannot change with time, the flow must be incompressible—even though pressure varies, the density must remain constant along a streamline; friction by viscous forces must be negligible. For conservative force fields (not limited to the gravitational field), Bernoulli's equation can be generalized as:
Psilocybin, a naturally occurring chemical in certain psychedelic mushrooms such as Psilocybe cubensis, is being studied for its ability to help people suffering from psychological disorders, such as obsessive–compulsive disorder. Minute amounts have been reported to stop cluster and migraine headaches. A double-blind study, done by Johns Hopkins Hospital, showed psychedelic mushrooms could provide people an experience with substantial personal meaning and spiritual significance. In the study, one third of the subjects reported ingestion of psychedelic mushrooms was the single most spiritually significant event of their lives. Over two-thirds reported it among their five most meaningful and spiritually significant events. On the other hand, one-third of the subjects reported extreme anxiety. However the anxiety went away after a short period of time. Psilocybin mushrooms have also shown to be successful in treating addiction, specifically with alcohol and cigarettes. A few species in the genus Amanita, most recognizably A. muscaria, but also A. pantherina, among others, contain the psychoactive compound muscimol. The muscimol-containing chemotaxonomic group of Amanitas contains no amatoxins or phallotoxins, and as such are not hepatoxic, though if not properly cured will be non-lethally neurotoxic due to the presence of ibotenic acid. The Amanita intoxication is similar to Z-drugs in that it includes CNS depressant and sedative-hypnotic effects, but also dissociation and delirium in high doses.
=== EC 1.1.3 With oxygen as acceptor === EC 1.1.3.1: Now included with EC 1.1.3.15 (S)-2-hydroxy-acid oxidase EC 1.1.3.2: L-lactate oxidase EC 1.1.3.3: malate oxidase EC 1.1.3.4: glucose oxidase EC 1.1.3.5: hexose oxidase EC 1.1.3.6: cholesterol oxidase EC 1.1.3.7: aryl-alcohol oxidase EC 1.1.3.8: L-gulonolactone oxidase EC 1.1.3.9: galactose oxidase EC 1.1.3.10: pyranose oxidase EC 1.1.3.11: L-sorbose oxidase EC 1.1.3.12: pyridoxine 4-oxidase EC 1.1.3.13: alcohol oxidase EC 1.1.3.14: catechol oxidase (dimerizing) EC 1.1.3.15: (S)-2-hydroxy-acid oxidase EC 1.1.3.16: ecdysone oxidase EC 1.1.3.17: choline oxidase EC 1.1.3.18: Secondary-alcohol oxidase EC 1.1.3.19: 4-hydroxymandelate oxidase EC 1.1.3.20: long-chain-alcohol oxidase EC 1.1.3.21: glycerol-3-phosphate oxidase EC 1.1.3.22: Now EC 1.17.3.2, xanthine oxidase.
Sources: en.wikipedia.org
=== Pyrolysis === In the typical operating temperature range of e-cigarettes (250–400 °C (482–752 °F)), 25–52% of CBD is transformed into other chemical substances: Δ9-THC, Δ8-THC, cannabinol and cannabichromene as predominant pyrolysates. From a chemical point of view, CBD in e-cigarettes can be considered a precursor of THC.
In 2023, Vasquez introduced bipartisan legislation aimed at addressing the teacher shortage in Indian Country. The bill proposed providing federal pension benefits to educators working in tribal schools, seeking to improve teacher retention and support Native American students. Vasquez voted that year in favor of requiring healthcare workers to receive the COVID-19 vaccine. The following day, he opposed a resolution to end the COVID-19 national emergency. On women's health, he has supported abortion rights and advocated for codifying Roe v. Wade into federal law. In 2024, Vasquez voted in favor of the Protecting Americans from Foreign Adversary Controlled Applications Act, sometimes called the TikTok ban, which sought to address concerns over data security and foreign influence. On July 19, he called for President Joe Biden to withdraw from the 2024 presidential election, citing concerns over his age and ability to campaign effectively. In December 2025, NBC News and The New York Times reported that Vasquez had voted against a bill to reopen the federal government and then touted the money the bill delivered to his district. After the federal government was reopened, primarily with Republican votes, after a 43-day shutdown, Vasquez was among Democrats who "claimed credit for some provisions in the bill." Former Speaker Nancy Pelosi coined the term "vote no and take the dough" when Republicans took credit for money brought to their districts under bills they opposed.
Trump to sidestep more confrontational interviews with professional journalists, where he might face tough questions, fact-checks and detailed policy debates. The influencers he met with rarely challenged Mr. Trump, and often lavished him with praise." Observers also highlighted Trump's courting of the "manosphere", a collection of what The Guardian described as "male podcasters, influencers and public figures" that "marketed themselves as free-thinking pundits who evaded the bounds of political classification". NYU marketing professor Scott Galloway said "this was the testosterone podcast election". Post-election research showed that nearly 40% of young voters got their news from social media influencers, and that a majority of those influencers leaned right. The New York Times reported that Trump's super PAC had joined a long list of presidential campaigns that made a "technological leap or innovation" while targeting key voters. The Times highlighted the use of targeted advertising of individual undecided voters on streaming video platforms that allowed the PAC to save money, while Harris largely targeted ads on streaming platforms by geography. It reported the Trump team's findings that the undecided electorate was younger, black, and Hispanic, and that such voters largely used streaming media over traditional broadcast television. Journalist Elizabeth Spiers argued that Trump's strong support among young white men could be attributed to his campaign "channeling what psychologists call 'hegemonic masculinity'".
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.